Coley HM - Search Results

1

The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.

Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE, Coley HM. Mehar A, et al. Among authors: coley hm. J Pharmacol Exp Ther. 2008 Mar;324(3):1181-7. doi: 10.1124/jpet.107.131383. Epub 2007 Dec 18. J Pharmacol Exp Ther. 2008. PMID: 18089846

2

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.

Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SE, Laing RW. Sooriakumaran P, et al. Among authors: coley hm. Anticancer Res. 2009 May;29(5):1483-8. Anticancer Res. 2009. PMID: 19443354 Free article. Clinical Trial.

3

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.

Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW, Smith CP, Laing EE, Coley HM. Sooriakumaran P, et al. Among authors: coley hm. Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):93-9. Cancer Genomics Proteomics. 2009. PMID: 19451093 Free article. Clinical Trial.

4

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.

Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Coley HM, et al. Biochem Pharmacol. 2006 Oct 16;72(8):941-8. doi: 10.1016/j.bcp.2006.07.022. Epub 2006 Aug 24. Biochem Pharmacol. 2006. PMID: 16934227

5

Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.

Coley HM, Shotton CF, Thomas H. Coley HM, et al. Anticancer Res. 2007 Jan-Feb;27(1A):273-8. Anticancer Res. 2007. PMID: 17352243 Free article.

6

COX-2 inhibition: a possible role in the management of prostate cancer?

Sooriakumaran P, Langley SE, Laing RW, Coley HM. Sooriakumaran P, et al. Among authors: coley hm. J Chemother. 2007 Feb;19(1):21-32. doi: 10.1179/joc.2007.19.1.21. J Chemother. 2007. PMID: 17309847 Review.

7

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP, Crook T. Coley HM, et al. Br J Cancer. 2012 Jan 31;106(3):482-9. doi: 10.1038/bjc.2011.566. Epub 2012 Jan 10. Br J Cancer. 2012. PMID: 22233925 Free PMC article.

8

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Coley HM, Hatzimichael E, Blagden S, McNeish I, Thompson A, Crook T, Syed N. Coley HM, et al. Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332. Oncotarget. 2012. PMID: 22289679 Free PMC article. Review.

9

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.

Coley HM. Coley HM. Cancer Treat Rev. 2008 Jun;34(4):378-90. doi: 10.1016/j.ctrv.2008.01.007. Epub 2008 Mar 25. Cancer Treat Rev. 2008. PMID: 18367336 Review.

10

The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.

Coley HM, Shotton CF, Kokkinos MI, Thomas H. Coley HM, et al. Gynecol Oncol. 2007 May;105(2):462-9. doi: 10.1016/j.ygyno.2007.01.004. Epub 2007 Feb 14. Gynecol Oncol. 2007. PMID: 17300833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters